KalVista Pharmaceuticals

76 articles with KalVista Pharmaceuticals

• KalVista Pharmaceuticals Provides Operational Update and Fiscal Year Financial Results - July 13, 2021

  7/13/2021

  KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, provided an operational update and released financial results for the fiscal year ended April 30, 2021.

• KalVista Pharmaceuticals Presents Data Showing Single On-Demand Treatment with Orally Administered KVD900 Significantly Slows Progression and Accelerates Resolution of Attacks in Patients with HAE

  7/12/2021

  KalVista Pharmaceuticals, Inc. today announced data presented for its oral drug candidates at the European Academy of Allergy and Clinical Immunology (EAACI) Congress.

• KalVista Pharmaceuticals to Present Data at the European Academy of Allergy and Clinical Immunology (EAACI)

  6/28/2021

  KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, announced acceptance of multiple abstracts at the European Academy of Allergy and Clinical Immunology Congress, from July 10-12, 2021.

• KalVista Pharmaceuticals Presents Phase 2 Clinical Data of Oral KVD900 for Treatment of HAE at C1-Inhibitor Deficiency & Angioedema Workshop

  6/5/2021

  KVD900 Efficacious Within First Hours of Attack and Significantly Shortens Time to Improvement of Attack Symptoms

• KalVista Pharmaceuticals to Present at Jefferies Virtual Healthcare Conference - May 27, 2021

  5/27/2021

  KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, announced it will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on Wednesday, June 2, 2021 at 10:30 a.m. ET.

• KalVista Pharmaceuticals to Present Clinical Data of KVD900 for the Oral Treatment of Hereditary Angioedema at the 12th C1-Inhibitor Deficiency & Angioedema Workshop

  5/10/2021

  KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, announced acceptance of an abstract for KVD900 as an oral presentation at the 12th C1-Inhibitor Deficiency & Angioedema Workshop, which will be held virtually from June 3-6, 2021.

• KalVista Pharmaceuticals Expands Senior Leadership Team with Appointment of Paul K. Audhya, MD, MBA as Chief Medical Officer

  5/3/2021

  KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, announced today the appointment of Paul K. Audhya, MD, MBA, as Chief Medical Officer.

• KalVista Pharmaceuticals Provides Regulatory Update for Phase 2 Clinical Trial of KVD824

  4/20/2021

  KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, announced that the U.S. Food and Drug Administration has notified the Company in a letter that it has placed a clinical hold on the proposed Phase 2 clinical trial of KVD824.

• 

  KalVista's Hereditary Angioedema Trial On Hold as FDA Requests Additional Data

  4/20/2021

  The agency is requesting additional information and analysis of preclinical studies regarding KVD824 before giving the go-ahead to the Phase II trial. 

• KalVista Pharmaceuticals Appoints Nancy Stuart to Board of Directors

  3/19/2021

  KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, announced today that Nancy Stuart has been appointed to its Board of Directors effective March 18, 2021.

• KalVista Pharmaceuticals Reports Third Fiscal Quarter Results

  3/11/2021

  – Recent KVD900 Phase 2 Clinical Trial Results Statistically and Clinically Significant – – IND Submitted for Oral Prophylactic HAE Treatment Candidate KVD824; Phase 2 Expected to Initiate in Q2 2021 – – Following Upsized Public Offering, Funded to KVD900 NDA Filing –

• KalVista Pharmaceuticals to Present at SVB Leerink Global Healthcare Conference

  2/18/2021

  KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced it will participate in a fireside chat at the 10th Annual SVB Leerink Global Healthcare Conference on Thursday, February 25, 2021 at 9:20 a.m. ET.

• KalVista Pharmaceuticals Announces the Closing of its Upsized Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

  2/16/2021

  KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the closing of its previously announced upsized public offering of 6,181,250 shares of its common stock at a price to the public of $36.00 per share before underwriting discounts and commissions, which included the exercise in full by the underwriters of their option to purchase 806,250 additional shares of KalVista’s common stock.

• KalVista Pharmaceuticals Announces Pricing of an Upsized $193.5 Million Public Offering of Common Stock

  2/11/2021

  KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the pricing of its upsized underwritten public offering of 5,375,000 shares of its common stock at a price to the public of $36.00 per share.

• KalVista Pharmaceuticals Reports Positive Results for KVD900 Phase 2 Demonstrating Statistically and Clinically Significant Responses Across All Endpoints as an Oral On-Demand Treatment for HAE Attacks

  2/9/2021

  – Oral KVD900 Primary Endpoint Shows Only 15% Use of Rescue Medication in Patients with Hereditary Angioedema (HAE) – – KVD900 Generally Safe and Well-Tolerated – – Conference Call to Discuss Trial Results Today at 8:30 a.m. ET –

• KalVista Pharmaceuticals Announces Proposed Public Offering of Common Stock - Feb 09, 2021

  2/9/2021

  KalVista Pharmaceuticals, Inc. announced that it intends to offer and sell 4,500,000 shares of its common stock in an underwritten public offering.

• KalVista Pharmaceuticals Reports Second Fiscal Quarter Results

  12/10/2020

  KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today provided an operational update and released financial results for the second fiscal quarter ended October 31, 202

• KalVista Pharmaceuticals to Present at Upcoming Investor Conferences - Nov 09, 2020

  11/9/2020

  KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, announced it will present a corporate overview at the following investor conferences

• KalVista Pharmaceuticals Reports First Fiscal Quarter Results

  9/14/2020

  KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today provided an operational update and released financial results for the first fiscal quarter ended July 31, 2020. “We are pleased that our KVD900 Phase

• KalVista Pharmaceuticals to Present at Cantor Global Healthcare Conference - Sep 11, 2020

  9/11/2020

  KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, announced that it will present at the Cantor Fitzgerald Virtual Global Healthcare Conference on Thursday, September 17, 2020 at 8:40 am ET.